Table 4.
Relationship of cumulative non-HDL-C burden to ASCVD incidence (sensitive analyses).
| HR (95% CI) of ASCVD | ||||
|---|---|---|---|---|
| Model 5 | Model 6 | Model 7 | Model 8 | |
| Durations of cumNon-HDL-C | ||||
| 0 year | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| 2 years | 1.29 (1.09–1.54) | 1.25 (1.06–1.47) | 1.27 (1.08–1.48) | 1.25 (1.04–1.49) |
| 4 years | 1.56 (1.28–1.91) | 1.53 (1.28–1.84) | 1.55 (1.30–1.85) | 1.51 (1.23–1.86) |
| 6 years | 2.04 (1.65–2.52) | 1.99 (1.64–2.41) | 1.91 (1.58–2.31) | 2.03 (1.63–2.51) |
| P trend | <0.001 | <0.001 | <0.001 | <0.001 |
| Quintiles of cumNon-HDL-C (mmol/L) | ||||
| <10.93 | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| 10.93–12.68 | 1.18 (0.91–1.52) | 1.09 (0.86–1.37) | 1.10 (0.87–1.40) | 1.19 (0.92–1.53) |
| 12.69–14.32 | 1.24 (0.96–1.59) | 1.16 (0.92–1.45) | 1.20 (0.96–1.50) | 1.18 (0.92–1.52) |
| 14.33–16.72 | 1.35 (1.06–1.72) | 1.23 (0.98–1.53) | 1.25 (1.01–1.56) | 1.31 (1.02–1.67) |
| ≥16.73 | 1.90 (1.50–2.39) | 1.70 (1.38–2.10) | 1.75 (1.42–2.15) | 1.83 (1.45–2.31) |
| P trend | <0.001 | <0.001 | <0.001 | <0.001 |
| Increase per SD | 1.10 (1.06–1.14) | 1.09 (1.06–1.13) | 1.10 (1.06–1.14) | 1.10 (1.06–1.14) |
| P trend | <0.001 | <0.001 | <0.001 | 0.007 |
Model 5 adjusted for model 3 and further excluded antihypertensive drugs. Model 6 adjusted for model 3 and further excluded hypoglycemic drugs. Model 7 adjusted for model 3 and further excluded lipid-lowing drugs use at baseline. Model 8 adjusted for model 3 and further excluded antihypertensive drugs, hypoglycemic drugs and lipid-lowing drugs use at baseline. ASCVD, atherosclerotic cardiovascular disease; HR, hazard ratio; non-HDL-C, non-high-density lipoprotein cholesterol; SD, standard deviation.